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INTRODUCTION:  Erdheim–Chester  disease  is  a rare,  non-Langerhans  histiocytosis  in which  pericardial
involvement  is diagnosed  with  increasing  frequency  and  is  associated  with  high mortality  rates.
PRESENTATION OF  CASE:  A 53-year-old  woman  presented  with  progressive  exertional  dyspnea  and  peri-
cardial  effusion  was  discovered.  Further  investigations  revealed  the  presence  of  a  diffuse,  inﬁltrating
process  and  a diagnosis  of Erdheim–Chester  disease  was  made.  An  emergent  pericardiocentesis  by  sub-
xiphoid  approach  was  completed  but  recurrent  drainage  obviated  removal  of the  pigtail  catheter.  A
pleuro-pericardial  window  was  placed using  video-assisted  thoracoscopic  surgery  (VATS)  and  analysis
of  the  resected  specimen  conﬁrmed  pericardial  involvement.ATS
ericardial effusion
istiocytosis
DISCUSSION: In this  case,  high  pericardial  ﬂuid  output  demanded  deﬁnitive  treatment  of the  pericardial
effusion.  Traditionally  this  would  be completed  via  thoracotomy.  VATS  is a minimally  invasive  alternative
which  permits  exploration  of  the  thoracic  cavity  and  the  creation  of  a pleuropericardial  window.
CONCLUSION: We  describe,  for  the  ﬁrst time,  the  successful  use  of VATS  for both  diagnostic  conﬁrma-
tion  and  therapeutic  relief  of  recurrent  pericardial  ﬂuid  drainage  due  to  pericardial  involvement  by
Erdheim–Chester  disease.
gical  © 2011 Sur
. Background
Erdheim–Chester disease (ECD) is a rare, non-Langerhans histi-
cytosis with multisystem involvement. These foamy histiocytes
re characterized by CD68 positivity and CD1a negativity on
mmunohistochemical staining. As CD68 is a histiocyte marker
nd CD1a is a marker for Langerhans cells, this ﬁnding distin-
uishes ECD from Langerhans cell histiocytosis.1 The most common
resentation is that of bone pain due to xanthomatous tissue
nﬁltration,2 however protean manifestations including disease
f the hypothalamic–pituitary axis, eyes, heart, lungs, retroperi-
oneum, and skin and heart has been described.3–5
Cardiovascular manifestations are frequently present (75%
f patients) but underdiagnosed clinically. Nonetheless, cardiac
nvolvement portends a poor prognosis and ultimately causes
eath in 31% of all cases.2
Interferon-alpha is considered ﬁrst line therapy and shows
 variable response depending on organs involved.6,7 However,
reatment is not standardized and varies according to clinician pref-
rence.
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More recently, pericardial involvement has been diagnosed with
increasing frequency and ranges from pericardial effusion more
commonly to pericardial constriction (24–44%).2,3 Video-assisted
thoracoscopic surgery (VATS) has potential for diagnosing cardiac
involvement and managing recurrent pericardial effusion in ECD.
VATS is a novel but attractive option because of its feasibility and
low morbidity in a variety of cardiac and thoracic condititions.8–12
The VATS procedure has real utility both as a diagnostic and ther-
apeutic procedure in the management of pericardial disease. We
report a case of ECD that highlights the role of VATS in obtaining a
biopsy to prove cardiac involvement and subsequently creating a
pericardial window to treat recurrent pericardial effusion.
2.  Case report
A  53-year-old woman  presented with progressive dyspnea
on exertion and lower extremity edema over a period of 1
year. Physical exam revealed heart rate 100/min, blood pressure
100/70 mmHg  with a pulsus paradoxus, elevated neck veins and a
positive Kussmauls sign. Cardiac sounds were distant and signiﬁ-
cant lower extremity edema was noted.
Initial laboratory results included an erythrocyte sedimentation
rate of 5 mm/h  and a C-reactive protein concentration of 18.2 mg/L
Open access under CC BY-NC-ND license.(normal range <8 mg/L) and a normal complete blood count and
metabolic panel. Chest X-ray showed an enlarged cardiac silhou-
ette and subsequent echocardiogram revealed a circumferential
pericardial effusion with evidence of tamponade. ECG showed low
NC-ND license. 
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hig. 1. CT reveals an extensive inﬁltrating process primarily affecting the kidneys
nd retroperitoneal area (region of white arrows).
oltage in the limb leads with evidence of electrical alternans.
n emergent pericardiocentesis by subxiphoid approach yielded
700 mL  of serous ﬂuid. A pigtail catheter was left in place to assist
ith further drainage. Cultures of the pericardial ﬂuid were nega-
ive for bacteria, fungus and acid fast bacilli, while cytology revealed
o malignant cells.
Computerized axial tomography (Siemens Somatom Sensation
4, Malvern, Pennsylvania) of the thorax, abdomen and pelvis
howed an inﬁltrative process primarily encasing the kidneys and
etroperitoneal structures (Fig. 1). A CT guided needle biopsy of
ig. 2. Pericardium. It is greatly thickened by dense eosinophilic connective tissue and in
ave  eosinophilic and others of which have foamy cytoplasm (b).PEN  ACCESS
ery Case Reports 3 (2012) 107– 110
the abnormal tissue in the left periaortic retroperitoneum revealed
ﬁbrosis with chronic inﬂammation including foamy macrophages,
which were CD68+ and reactive with antibodies to S100 protein
(Fig. 2). A subsequent skeletal survey was  normal. A technetium
whole body scan revealed tracer uptake at the mandible diffusely,
mid and distal sternum, proximal humeri, distal femurs and dis-
tal tibia bilaterally. MRI  head demonstrated bilateral intraconal
masses, approximately 1.5 cm in diameter, centered between the
optic nerve and lateral rectus muscle.
Persistent drainage of pericardial ﬂuid (>100 mL  daily) obvi-
ated removal of the catheter. To facilitate drainage a pericardial
window was  placed. Under general anesthesia, the patient was
placed in the left lateral decubitus position and three ports were
inserted between the fourth and sixth intercostal spaces in the right
hemithorax (Fig. 3). Following dissection of adhesions between
lung, chest wall and pericardium, a large segment of pericardium
measuring 5.5 cm ×3.7 cm × 0.2 cm was removed freeing com-
pletely the right atrium and a portion of the upper right ventricle.
This resection formed the pericardial window. Pathology conﬁrmed
a mild chronic ﬁbrosing pericarditis associated with an inﬁltrate of
foamy and eosinophilic histiocytes. These histiocytes were CD68+,
and had negative antibody reactivity to S100 protein and CD1a. A
diagnosis of ECD with cardiac involvement was established.
There were no surgical complications and the patient was dis-
charged on post operative day 4. At four months follow-up there
was no recurrence of the pericardial effusion.
3. Discussion
William Chester a cardiology fellow working under the pathol-
ogist Jakob Erdheim in Vienna, ﬁrst described 2 cases of ‘lipoid
granulomatosis’ in 1930.13 This disease later became known as
Erdheim–Chester disease (ECD).14 Biopsy is required for deﬁnitive
diagnosis, with pathology showing CD68+/CD1a− non-Langerhans
histiocytes. There is variable reactivity for S100 protein, a marker
ﬂammation (a). The cellular inﬁltrate is comprised of macrophages, some of which
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Fig. 3. Positioning of ports intraoperatively. The patient is draped and in the left
lateral decubitus position. Three ports are in situ between the fourth and sixth
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use of VATS to diagnose cardiac involvement in Erdheim–Chester
T
Sntercostal  spaces in the right hemithorax.
lso present in other disorders of histiocytes.1 Inﬁltration of the
ones and other organs by these foamy histiocytes lead to a variety
f clinical presentations. Typically, bone pain is the most fre-
uent symptom,2,5,15 with underlying cortical osteosclerosis of
ong bones and abnormally increased labeling in the long bones
f the lower limbs on technetium-99 bone scans.5,15,16 Half of
atients however have extra-skeletal manifestations including
xophthalmos, interstitial lung disease, diabetes insipidus, and
anthelasma.3,5,17
Interferon-alpha is generally used as ﬁrst line therapy for
CD, but given the variable response, treatment is individual-
zed depending on extent and severity of organ involved.6,7 A
ultitude of treatments for ECD have been proposed including
arious cytotoxic agents, steroids, radiation therapy and stem cell
ransplantation.5,18,19 Analysis of the various therapies is difﬁcult
able 1
election of treatments previously used for ECD and outcomes.
Author, year No. patients Treatment 
Haroche et al., 20057 8 Interferon alpha: 3–9 × 106 units 3
times  weekly for median of
23 months
Myra et al., 200423 1 Cladribine: 0.14 mg/kg/day for 5
consecutive days every 4 weeks. 6
courses
Miller
et  al.,
200618
9 Radiotherapy (for palliation
purposes):
10–24 Gy (median, 16 Gy) in 5–12
fractions  (median, 8) at
1.8–2.0  Gy/d (median, 2.0 Gy/d)
Haroche
et al.,
200824
6 Imatinib mesylate (for
severe/resistant  disease):
Initially 100 mg/day, increasing
according to tolerence + efﬁcacy
Boissel  et al., 200118 1 Double autologous hematopoietic
stem  cell transplant (conditioning
with etoposide and melphalan;
post  conditioning with carmustine)PEN  ACCESS
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as  response is often not stated and followup periods are short
(Table 1).
We  describe a patient with multisystem involvement by ECD.
Two biopsies from different anatomical sites exhibited the typical
CD68+/CD1a− histiocytes, and different reactivity to S100 protein.
Our patient presented with life-threatening pericardial effusion
with tamponade apparent on physical exam and echocardiography.
Cardiac involvement by ECD is common and is associated
with high mortality rates.2 In our patient, pericardiocentesis was
therapeutic initially but persistent high pericardial ﬂuid output
demanded deﬁnitive treatment of the pericardial effusion with
pericardiotomy or ‘window’ insertion. Traditionally, this would be
completed via thoracotomy. Currently, subxiphoid pericardiotomy
and video-assisted thoracoscopic surgery are the most commonly
employed techniques for management of recurrent pericardial
effusions.
VATS is a minimally invasive alternative which permits explo-
ration of the thoracic cavity and the creation of a pleuro-pericardial
window.20 It is an appealing new option for the management of
many cardiothoracic diseases.8–11,20 It combines the advantages of
subxiphoid pericardiotomy and thoracotomy.20
Compared with thoracotomy, the VATS procedure is being used
increasingly for management of recurrent pericardial effusions,
as it has less post-operative pain and less effect on pulmonary
dysfunction.11 Patients in whom collection of a biopsy specimen is
important, VATS when compared to subxiphoid approaches offers
an increased area of exposure at lower risk to allow for pericardial
biopsy.20–22 VATS is also associated with a lower rate of effusion
recurrence when compared with subxiphoid approaches (Table 1).
The choice of procedure, depends signiﬁcantly on local expertise.
In  our case, VATS provided a viable option for both diagnostic
conﬁrmation and therapeutic relief of recurrent pericardial ﬂuid
drainage.
To our knowledge, this is the ﬁrst reported case of the successfuldisease and to treat recurrent pericardial effusion through forma-
tion of a pericardial window.
Anatomical involvement Outcome
Multisystem including: bone,
renal, cardiovascular, CNS.
Efﬁcacious  in 6 patients: xanthelasma
disappeared in 2; hydronephrosis
regressed  in 2, papilledema
disappeared  in 1, exophthalmos
disappeared  in 2, variable regression of
coated aorta. 2/5 with CV involvement
died.
Orbital, cardiac, bone and lung Regression of bone, lung and orbital
disease at two  years
Osseous  sites × 6; brain
sites × 2, retroorbital × 1
Osseous sites: pain scores improved at
1 year post therapy
Brain: initial improvement in
symptoms but progression by
4 months post therapy
Retro-orbital: pain free at 1 year with
decrease in size of mass
Multisystem including: CNS,
cardiovascular, bone
CNS  involvement worsened in 75%
cases, cardiovascular disease remained
stable in 80%, bone involvement
worsened.
Renal,  facial bones and
retroorbital involvement
Improvement in retroorbital disease,
facial tumor and kidney tumor.
Improvement stable at 2 years
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. Conclusion
ECD disease is a rare entity with a large proportion of cases hav-
ng cardiac involvement, speciﬁcally pericardial disease. VATS is a
ovel and appealing way both to diagnose and to manage recurrent
ericardial effusions in ECD. VATS is associated with a lower mor-
idity and mortality than traditional thoracotomy or subxiphoid
ericardial window procedures.
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